- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04976322
En studie för att utvärdera säkerheten och tolerabiliteten av Dapirolizumab Pegol hos studiedeltagare med systemisk lupus erythematosus
En multicenter, öppen förlängningsstudie för att utvärdera den långsiktiga säkerheten och tolerabiliteten av Dapirolizumab Pegol-behandling hos studiedeltagare med systemisk lupus erythematosus
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Buenos Aires, Argentina
- Sl0046 60002
-
Mendoza, Argentina
- Sl0046 60029
-
Quilmes, Argentina
- Sl0046 60003
-
Quilmes, Argentina
- Sl0046 60022
-
San Juan, Argentina
- Sl0046 60011
-
San Miguel de Tucumán, Argentina
- Sl0046 60014
-
-
-
-
-
Brussels, Belgien
- Sl0046 40123
-
-
-
-
-
Plovdiv, Bulgarien
- Sl0046 40189
-
Sofia, Bulgarien
- Sl0046 40380
-
-
-
-
-
Santiago, Chile
- Sl0046 60018
-
Santiago, Chile
- Sl0046 60015
-
-
-
-
-
Barranquilla, Colombia
- Sl0046 60013
-
Barranquilla, Colombia
- Sl0046 60019
-
Bogotá, Colombia
- Sl0046 60006
-
Bogotá, Colombia
- Sl0046 60027
-
Bucaramanga, Colombia
- Sl0046 60016
-
Chía, Colombia
- Sl0046 60007
-
Montería, Colombia
- Sl0046 60031
-
-
-
-
-
Davao City, Filippinerna
- Sl0046 20182
-
Makati, Filippinerna
- Sl0046 20181
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35294
- Sl0046 50140
-
-
Arizona
-
Avondale, Arizona, Förenta staterna, 85392
- Sl0046 50058
-
Glendale, Arizona, Förenta staterna, 85306
- Sl0046 50662
-
Phoenix, Arizona, Förenta staterna, 85032
- Sl0046 50052
-
Tucson, Arizona, Förenta staterna, 85704
- Sl0046 50328
-
-
California
-
Beverly Hills, California, Förenta staterna, 90210
- Sl0046 50383
-
La Palma, California, Förenta staterna, 90623-1730
- Sl0046 50275
-
San Leandro, California, Förenta staterna, 94578
- Sl0046 50316
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80230
- Sl0046 50339
-
-
Florida
-
Brandon, Florida, Förenta staterna, 33511
- Sl0046 50239
-
Gainesville, Florida, Förenta staterna, 32610
- Sl0046 50362
-
Miami, Florida, Förenta staterna, 33172
- Sl0046 50681
-
Ormond Beach, Florida, Förenta staterna, 32174
- Sl0046 50059
-
Plantation, Florida, Förenta staterna, 33324
- Sl0046 50324
-
Tampa, Florida, Förenta staterna, 33606
- Sl0046 50329
-
Tampa, Florida, Förenta staterna, 33618
- Sl0046 50698
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30303
- Sl0046 50368
-
-
Idaho
-
Idaho Falls, Idaho, Förenta staterna, 83404
- Sl0046 50240
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60616
- Sl0046 50699
-
-
Kentucky
-
Hopkinsville, Kentucky, Förenta staterna, 42240-1746
- Sl0046 50474
-
-
Louisiana
-
Lake Charles, Louisiana, Förenta staterna, 70605
- Sl0046 50285
-
New Orleans, Louisiana, Förenta staterna, 70112
- Sl0046 50660
-
-
Maryland
-
Hagerstown, Maryland, Förenta staterna, 21740
- Sl0046 50015
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Sl0046 50219
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89128
- Sl0046 50273
-
-
New York
-
Canton, New York, Förenta staterna, 13617
- Sl0046 50366
-
Manhasset, New York, Förenta staterna, 11030
- Sl0046 50264
-
New York, New York, Förenta staterna, 10032
- Sl0046 50334
-
-
North Carolina
-
Charlotte, North Carolina, Förenta staterna, 28211
- Sl0046 50238
-
-
Pennsylvania
-
Hershey, Pennsylvania, Förenta staterna, 17033
- Sl0046 50147
-
-
Tennessee
-
Jackson, Tennessee, Förenta staterna, 38305
- Sl0046 50001
-
-
Texas
-
Bellaire, Texas, Förenta staterna, 77401
- Sl0046 50738
-
Colleyville, Texas, Förenta staterna, 76034
- Sl0046 50418
-
-
West Virginia
-
Beckley, West Virginia, Förenta staterna, 25801
- Sl0046 50050
-
-
-
-
-
Athens, Grekland
- Sl0046 40378
-
Athens, Grekland
- Sl0046 40501
-
Crete, Grekland
- Sl0046 40377
-
Larissa, Grekland
- Sl0046 40507
-
-
-
-
-
Catania, Italien
- Sl0046 40084
-
Milan, Italien
- Sl0046 40448
-
-
-
-
-
Nagoya, Japan
- Sl0046 20287
-
-
-
-
-
Calgary, Kanada
- Sl0046 50374
-
Edmonton AB, Kanada
- Sl0046 50337
-
Rimouski, Kanada
- Sl0046 50259
-
Toronto, Kanada
- Sl0046 50045
-
-
-
-
-
Beijing, Kina
- Sl0046 20128
-
Changchun, Kina
- Sl0046 20291
-
Guangzhou, Kina
- Sl0046 20019
-
Guilin, Kina
- Sl0046 20290
-
Shanghai, Kina
- Sl0046 20020
-
Shantou, Kina
- Sl0046 20346
-
Suzhou, Kina
- Sl0046 20204
-
Tianjin, Kina
- Sl0046 20136
-
Wenzhou, Kina
- Sl0046 20025
-
Wuhan, Kina
- Sl0046 20180
-
Yangzhou, Kina
- Sl0046 20273
-
Zhengzhou, Kina
- Sl0046 20132
-
-
-
-
-
Chihuahua City, Mexiko
- Sl0046 50317
-
Cuernavaca, Mexiko
- Sl0046 50250
-
Guadalajara, Mexiko
- Sl0046 50249
-
León, Mexiko
- Sl0046 50271
-
Monterrey, Mexiko
- Sl0046 50251
-
Mérida, Mexiko
- Sl0046 50252
-
-
-
-
-
Lima, Peru
- Sl0046 60023
-
Lima, Peru
- Sl0046 60009
-
-
-
-
-
Bialystok, Polen
- Sl0046 40482
-
Bydgoszcz, Polen
- Sl0046 40119
-
Katowice, Polen
- Sl0046 40398
-
Krakow, Polen
- Sl0046 40502
-
Lublin, Polen
- Sl0046 40151
-
Poznan, Polen
- Sl0046 40044
-
Poznan, Polen
- Sl0046 40090
-
Warsaw, Polen
- Sl0046 40097
-
Warsaw, Polen
- Sl0046 40098
-
Wroclaw, Polen
- Sl0046 40397
-
Wroclaw, Polen
- Sl0046 40481
-
-
-
-
-
Caguas, Puerto Rico
- Sl0046 50671
-
-
-
-
-
Galati, Rumänien
- Sl0046 40382
-
-
-
-
-
Belgrade, Serbien
- Sl0046 40393
-
Belgrade, Serbien
- Sl0046 40461
-
Belgrade, Serbien
- Sl0046 40730
-
Novi Sad, Serbien
- Sl0046 40392
-
-
-
-
-
Barcelona, Spanien
- Sl0046 40160
-
Málaga, Spanien
- Sl0046 40341
-
Sabadell, Spanien
- Sl0046 40101
-
Vigo, Spanien
- Sl0046 40099
-
-
-
-
-
Incheon, Sydkorea
- Sl0046 20108
-
Seoul, Sydkorea
- Sl0046 20104
-
-
-
-
-
Taichung, Taiwan
- Sl0046 20113
-
Taichung, Taiwan
- Sl0046 20142
-
Taipei, Taiwan
- Sl0046 20095
-
Taiyuan, Taiwan
- Sl0046 20082
-
-
-
-
-
Prague, Tjeckien
- Sl0046 40066
-
-
-
-
-
Cologne, Tyskland
- Sl0046 40386
-
Freiburg im Breisgau, Tyskland
- Sl0046 40072
-
Herne, Tyskland
- Sl0046 40027
-
Leipzig, Tyskland
- Sl0046 40078
-
Tübingen, Tyskland
- Sl0046 40402
-
Vogelsang-gommern, Tyskland
- Sl0046 40715
-
-
-
-
-
Budapest, Ungern
- Sl0046 40412
-
Debrecen, Ungern
- Sl0046 40411
-
Szeged, Ungern
- Sl0046 40031
-
Székesfehérvár, Ungern
- Sl0046 40499
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment
- The participant completed one of the parent studies within 4 weeks prior to entry to this study
Exclusion Criteria:
- Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Dapirolizumab pegol
Subjects will receive dapriolizumab pegol throughout the Treatment Period. |
Subjects will receive dapirolizumab pegol at prespecified time-points.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of treatment-emergent adverse events (TEAEs) during the study
Tidsram: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment. |
From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
|
Incidence of serious treatment-emergent adverse events during the study
Tidsram: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
A serious treatment-emergent adverse event (serious TEAE) is any untoward medical occurrence that at any dose:
|
From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
|
Incidence of treatment-emergent adverse events (TEAEs) leading to permanent dapirolizumab pegol discontinuation
Tidsram: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, and leading to permanent drug discontinuation whether or not these events are related to study treatment. |
From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 24
Tidsram: Week 24
|
BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010). |
Week 24
|
|
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 52
Tidsram: Week 52
|
BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010). |
Week 52
|
|
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 104
Tidsram: Week 104
|
BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010). |
Week 104
|
|
Achievement of LLDAS at ≥50% of all visits
Tidsram: From Baseline (Day 1) until End of Treatment (Week 104)
|
Low lupus disease activity state (LLDAS) is defined as:
|
From Baseline (Day 1) until End of Treatment (Week 104)
|
|
Achievement of BICLA response at Week 24
Tidsram: Week 24
|
A study participant is considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following is fulfilled:
The parent studies Baseline will be used as reference point. |
Week 24
|
|
Achievement of BICLA response at Week 52
Tidsram: Week 52
|
A study participant is considered to be a BICLA responder if all of the following is fulfilled:
The parent studies Baseline will be used as reference point. |
Week 52
|
|
Achievement of BICLA response at Week 104
Tidsram: Week 104
|
A study participant is considered to be a BICLA responder if all of the following is fulfilled:
The parent studies Baseline will be used as reference point. |
Week 104
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: UCB Cares, 001 844 599 2273 (UCB)
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SL0046
- 2019-003409-83 (EudraCT-nummer)
- U1111-1293-7098 (Annan identifierare: World Health Organization (WHO))
- 2023-506368-14 (Registeridentifierare: EU Clinical Trials)
- 2023 (U.S.S. NIH-anslag/kontrakt)
- 2019 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Tidsram för IPD-delning
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Kriterier för IPD Sharing Access
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .